Purple Biotech’s CM24 Shows Promising Cancer Results

Purple Biotech (PPBT) has released an update.

Purple Biotech announced positive results from its Phase 2 study of CM24 for pancreatic cancer, showing significant improvements in survival rates when combined with nivolumab and chemotherapy. The study highlights its potential as a promising treatment option with a 79% reduction in risk of death in certain biomarker-enriched patient groups. Investors may find these results encouraging as the company moves forward with plans for further clinical studies.

For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.